Skip to main content

Table 1 Selected demographic and clinical characteristics of rheumatoid arthritis patients stratified by the presence of ischaemic heart disease

From: Interaction between smoking and functional polymorphism in the TGFB1 gene is associated with ischaemic heart disease and myocardial infarction in patients with rheumatoid arthritis: a cross-sectional study

Variable All patients
(n= 414)
Patients without IHD (n= 328) Patients with IHD (n= 86) Pvaluea
Age, years 62.0 (54.8-69.0) 61.0 (54.0-68.0) 67.0 (58.0-72.3) < 0.0001
Age of onset, years 50.0 (41.0-58.0) 49.0 (40.0-56.2) 54.9 (44.3-63.2) 0.0022
Duration, years 10.0 (3.6-18.0) 10.0 (3.0-18.0) 8.0 (4.0-18.0) NS
Male/female 136/278 91/237 45/41 < 0.0001
Body mass index 27.3 (24.6-30.4) 27.3 (24.4-30.3) 27.4 (25.4-31.0) NS
Rheumatoid factor 236/412 (57.3%) 178/326 (54.6%) 58/86 (67.4%) 0.032
Anti-CCP 305/402 (75.9%) 243/320 (75.9%) 62/82 (75.6%) NS
ESR 20 (10-37) 18 (10-34) 26 (10-43.5) NS
CRP (≥ 10 mg/L) 223/414 (53.9%) 162/328 (49.4%) 61/86 (70.9%) 0.0004
Nodules 54/414 (13.0%) 41/328 (12.5%) 13/86 (15.1%) NS
Erosions 301/407 (74.0%) 243/322 (75.5%) 58/85 (68.2%) NS
DAS28b 4.2 (1.4%) 4.1 (1.4%) 4.4 (1.4%) NS
HAQ score 1.6 (1.0-2.0) 1.6 (0.9-2.0) 1.8 (1.3-2.3) 0.014
Ever-smoker 276/414 (66.7%) 205/328 (62.5%) 71/86 (82.6%) 0.0004
Current smoker 74/414 (17.9%) 58/328 (17.7%) 16/86 (18.6%) NS
Previous MI 52/414 (12.6%) - 52/86 (60.5%) -
Hypertension 161/413 (39.0%) 110/327 (33.6%) 51/86 (59.3%) < 0.0001
Hypercholesterolemia 68/414 (16.4%) 39/328 (11.9%) 29/86 (33.7%) < 0.0001
Diabetes (I and II) 30/414 (7.3%) 13/328 (4.0%) 17/86 (19.8%) < 0.0001
DMARD use 386/413 (93.5%) 306/327 (93.6%) 80/86 (93.0%) NS
Methotrexate use 242/413 (58.6%) 204/327 (62.4%) 38/86 (44.2%) 0.0023
Steroid use 40/413 (9.7%) 28/327 (8.6%) 12/86 (14.0%) NS
Biologic agent use 60/413 (14.5%) 53/327 (16.2%) 7/86 (8.1%) NS
Serum TGF-β1 level, pg/mL 16,908 (12,744-21,428) 16,764 (12,422-21,772) 17,156 (13,435-20,533) NS
  1. Values other than P values are presented as number (percentage) or median (interquartile range). aP values show significant differences between patients with and those without IHD (unadjusted); bmean (standard deviation). Anti-CCP, anti-cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, Disease Activity Score using 28 joint counts; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; IHD, ischemic heart disease; MI, myocardial infarction; NS, non-significant; TGF-β1, transforming growth factor-beta-1.